According to Zacks, “AVEO is a development-stage biopharmaceutical company focused on the development of cancer treatments. We are encouraged by the company’s progress with its lead pipeline candidate, tivozanib. Tivozanib is under review in the EU for the first-line treatment of renal cell carcinoma (RCC). Currently, the candidate is being evaluated in a couple of studies for the third-line treatment of RCC and advanced RCC. Meanwhile, AVEO is quite active on the partnering front. It has partnerships with Ophthotech and EUSA Pharma for tivozanib. Moreover, securing Novartis as a partner for cachexia candidate, AV-380, represents a huge positive for the company. Such deals provide the company with funds in the form of upfront and milestone payments. On the flip side, termination of the Pharmstandard agreement for tivozanib is concerning. Going forward, any hiccup on the development/regulatory front would impact its shares negatively.”
A number of other research firms also recently weighed in on AVEO. FBR & Co restated a buy rating on shares of AVEO Pharmaceuticals in a research note on Tuesday, September 13th. Piper Jaffray Cos. restated a buy rating on shares of AVEO Pharmaceuticals in a research note on Thursday, June 16th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 0.035% during midday trading on Wednesday, reaching $0.868. 11,365 shares of the company’s stock traded hands. The stock’s market cap is $65.85 million. AVEO Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $1.47. The stock has a 50-day moving average price of $0.91 and a 200-day moving average price of $0.95.
A number of large investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in AVEO Pharmaceuticals by 6.0% in the first quarter. Renaissance Technologies LLC now owns 2,094,900 shares of the biopharmaceutical company’s stock valued at $1,927,000 after buying an additional 119,000 shares in the last quarter. New Leaf Venture Partners L.L.C. acquired a new stake in AVEO Pharmaceuticals during the second quarter valued at approximately $2,490,000. Bridgeway Capital Management Inc. increased its stake in AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 200,000 shares in the last quarter. Spark Investment Management LLC acquired a new stake in AVEO Pharmaceuticals during the second quarter valued at approximately $281,000. Finally, Perceptive Advisors LLC acquired a new stake in AVEO Pharmaceuticals during the second quarter valued at approximately $2,987,000. Institutional investors and hedge funds own 39.10% of the company’s stock.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.